Alnylam Pharmaceuticals
Utility Patents

Last updated:

List of all Alnylam Pharmaceuticals patents 89 in total

Status Patent
Grant
Utility: Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 5 Jan 2021
Grant
Utility: Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder External link
Filling date: 9 Sep 2025 Issue date: 1 Dec 2020
Grant
Utility: Glucokinase (GCK) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 24 Nov 2020
Grant
Utility: TMPRSS6 iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 10 Nov 2020
Grant
Utility: Angiotensinogen (AGT) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 27 Oct 2020
Grant
Utility: Carbohydrate conjugates as delivery agents for oligonucleotides External link
Filling date: 9 Sep 2025 Issue date: 20 Oct 2020
Grant
Utility: Oligonucleotide-ligand conjugates and process for their preparation External link
Filling date: 9 Sep 2025 Issue date: 20 Oct 2020
Grant
Utility: Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 8 Sep 2020
Grant
Utility: Compositions and methods for inhibiting expression of CD274/PD-L1 gene External link
Filling date: 9 Sep 2025 Issue date: 18 Aug 2020
Grant
Utility: Compositions and methods for inhibiting expression of the LECT2 gene External link
Filling date: 9 Sep 2025 Issue date: 18 Aug 2020
Grant
Utility: Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 14 Jul 2020
Grant
Utility: Serpina1 iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 16 Jun 2020
Grant
Utility: Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases External link
Filling date: 9 Sep 2025 Issue date: 16 Jun 2020
Grant
Utility: Modified iRNA agents External link
Filling date: 9 Sep 2025 Issue date: 9 Jun 2020
Grant
Utility: Therapeutic compositions External link
Filling date: 9 Sep 2025 Issue date: 2 Jun 2020
Grant
Utility: Modified RNAi agents External link
Filling date: 9 Sep 2025 Issue date: 2 Jun 2020
Grant
Utility: Compositions and methods directed to treating liver fibrosis External link
Filling date: 9 Sep 2025 Issue date: 2 Jun 2020
Grant
Utility: Hepatitis D virus (HDV) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 5 May 2020
Grant
Utility: Modified double-stranded RNA agents External link
Filling date: 9 Sep 2025 Issue date: 7 Apr 2020
Grant
Utility: Modified double-stranded RNA agents External link
Filling date: 9 Sep 2025 Issue date: 7 Apr 2020
Grant
Utility: Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 24 Mar 2020
Grant
Utility: Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 25 Feb 2020
Grant
Utility: RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases External link
Filling date: 9 Sep 2025 Issue date: 25 Feb 2020
Grant
Utility: Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 11 Feb 2020
Grant
Utility: Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 4 Feb 2020
Grant
Utility: Monomers and oligonucleotides comprising cycloaddition adduct(s) External link
Filling date: 9 Sep 2025 Issue date: 4 Feb 2020
Grant
Utility: Hepatitis B virus (HBV) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 24 Dec 2019
Grant
Utility: Compositions and methods for inhibiting expression of the PCSK9 gene External link
Filling date: 9 Sep 2025 Issue date: 10 Dec 2019
Grant
Utility: Compositions and methods for inhibiting expression of factor V External link
Filling date: 9 Sep 2025 Issue date: 10 Dec 2019
Grant
Utility: Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 3 Dec 2019
Grant
Utility: Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression External link
Filling date: 9 Sep 2025 Issue date: 19 Nov 2019
Grant
Utility: Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene External link
Filling date: 9 Sep 2025 Issue date: 12 Nov 2019
Grant
Utility: Complement component iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 5 Nov 2019
Grant
Utility: Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 10 Sep 2019
Grant
Utility: Compositions and methods for inhibiting expression of the ALAS1 gene External link
Filling date: 9 Sep 2025 Issue date: 3 Sep 2019
Grant
Utility: Polynucleotide agents targeting complement component C5 and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 3 Sep 2019
Grant
Utility: Oligonucleotide end caps External link
Filling date: 9 Sep 2025 Issue date: 20 Aug 2019
Grant
Utility: Ketohexokinase (KHK) iRNA compositions and methods of use thereof External link
Filling date: 9 Sep 2025 Issue date: 6 Aug 2019
Grant
Utility: Biodegradable lipids for the delivery of active agents External link
Filling date: 9 Sep 2025 Issue date: 6 Aug 2019

Showing 50 to 89 of 89 patents.